2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1032

Neutralization of IL-17 Ameliorated Kidney Pathology Associated with Immune-Complex Mediated Autoimmune Glomerulonephritis
Abstract Number: 1593

Neutrophil-Lymphocyte Ratio As a Marker of Disease Activity in Psoriatic Arthritis
Abstract Number: 1610

New Autoantigens Associated with Lupus Nephritis
Abstract Number: 2898

New Insights into the Primary Care Osteoarthritis Consultation with Implications for Practice
Abstract Number: 2204

New Onset Vitiligo Under Biological Agents: A Case Series
Abstract Number: 314

Next Generation Sequencing Reveals Restriction of the Treg Cell Repertoire and an Abundance of Shared Synovial Treg Clonotypes in JIA
Abstract Number: 1960

NF-κB-Inducing Kinase (NIK) Is Expressed in Synovial Endothelial Cells in Early Arthritis Patients and Correlates with Local Disease Activity and Systemic Markers of Inflammation
Abstract Number: 1203

NK/NKT Cells from Early and Definite Systemic Sclerosis Patients Show Different Immunological Responses after IL-2 Stimulation
Abstract Number: 315

NLRC4-Related Macrophage Activation Syndrome (NLRC4-MAS): A Novel Primary Autoinflammatory Syndrome Caused By Activating Mutations in NLRC4
Abstract Number: 2047

No Association of Serum Uric Acid with Hip Fracture Risk in Older Men and Women from the Framingham Original Cohort
Abstract Number: 2617

No Evidence of Accelerated Atheromatosis, Increased Arterial Stiffness or Hypertrophy in Ankylosing Spondylitis: A Systematic Case-Control Study
Abstract Number: 1838

No Increased Risk of Developing a First Invasive Melanoma in Rheumatoid Arthritis Patients Treated with Biologics: Results of a Collaborative Project of 11 European Biologics Registers
Abstract Number: 832

NOD2-Associated Autoinflammatory Disease: The Largest Cohort Study
Abstract Number: 2399

Non-Adherence to Disease-Modifying Anti-Rheumatic Drugs in Patients with Rheumatoid Arthritis: An Italian Survey
Abstract Number: 2802

Non-Canonical NF-Kappab Signaling Promotes Angiogenesis in a Novel 3D Spheroid Model of Rheumatoid Arthritis Synovial Inflammation

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].